Dr. Balak Das Kurmi

About

I, Dr. Balak Das Kurmi (M. Pharm, PhD), have more than 15 years of Academic/Research experience. Presently working as Professor of Pharmaceutics and Head of the Department of Quality Assurance and Regulatory Affairs, at ISF College of Pharmacy, Moga, Punjab, INDIA.
I have completed B. Pharm and M. Pharm (Pharmaceutics) from the Department of Pharmaceutical Sciences, Dr Hari Singh Gour Central University, Sagar, M.P., India, and was awarded PhD from the School of Studies in Natural Resources, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G.) India.
My research work is primarily focused on drug delivery and advanced formulation development of different Novel Drug Delivery Systems such as Liposomes, Nanoparticles, Micelles, and Dendrimers using Quality by Design (QbD)-assisted strategies.
I have acquired some recognizable career milestones as follows:
1. Awarded DST-SERB, CSIR, and ICMR Senior Research Fellowship during his PhD, and simultaneously awarded an International Travel Grant from CSIR-New Delhi.
2. Published >185 research/review articles, 06 Books/>25 Book Chapters in peer-reviewed internationally recognised publishers, and participated in >100 conferences/ seminars/ workshops and given oral talks and presentations.
3. Recipient of the Prof. Ambika Nandan Mishra Memorial Best Scientist Award (Year 2023) and the Prof. Jainendra Jain Memorial Best Young Researcher Award (2024).
4. Secured two ICMR, one DST-SERB, one MSME, and one DHR Research Project Grants.
5. Supervised 28 M. Pharm and presently 10 M. Pharm and 05 PhD scholars are working in my lab.

Employment

• ISF College of Pharmacy Professor (Pharmaceutics) and Head
  2021 - Present
• Guru Ghasidas Vishwavidyalaya PhD (CSIR-Senior Research Fellow)
  2018 - 2020
• Guru Ghasidas Vishwavidyalaya DST-SERB Research Fellow
  2014 - 2017
• Guru Ramdas Khalsa Institute of Science and Technology (Pharmacy) Assistant Professor
  2010 - 2014

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (137)

• In Silico Exploration of Algal-Derived Anticancer Agents: Insights from Molecular Docking, Dynamics, DFT and Toxicity Profiling
  Journal of Computational Biophysics and Chemistry 2026 DOI: 10.1142/S2737416525501157
  +Save
• Advancing Preclinical Oncology: Next‐Generation Mouse Models for Decoding Tumor Progression and Metastasis
  Advanced Therapeutics 2026 DOI: 10.1002/adtp.70167
  +Save
• Next-Generation Genome Editing: Overcoming CRISPR-Cas9 Limitations with Prime Editing and PASTE Technology
  Current Pharmacogenomics and Personalized Medicine 2026 DOI: 10.2174/0118756921492763260804044215
  +Save
• Polymer-doxorubicin Conjugates: Redefining Chemotherapy for Breast Cancer
  Mini-Reviews in Medicinal Chemistry 2026 DOI: 10.2174/0113895575471485260408204857
  +Save
• Emrelis for c-Met Positive NSCLC: A Breakthrough in Antibody-Drug Conjugate-based Treatment Approved by the FDA
  Anti-Cancer Agents in Medicinal Chemistry 2026 DOI: 10.2174/0118715206446635251226113107
  +Save
• Ocular drug delivery in the era of nanomedicine, gene therapy, and digital twins
  Journal of Drug Delivery Science and Technology 2026 DOI: 10.1016/j.jddst.2026.108318
  +Save
• Bioinspired and stimuli-responsive vaginal nanocarrier platforms for targeted infection eradication and epithelial barrier restoration
  Nano Trends 2026 DOI: 10.1016/j.nwnano.2026.100210
  +Save
• Revisiting Raynaud’s Phenomenon: Emerging Insights and Evolving Management Strategies
  Recent Advances in Inflammation & Allergy Drug Discovery 2026 DOI: 10.2174/0127722708444234260422070300
  +Save
• Cyclodextrins: Synthesis, Pharmaceutical Applications, Drug Delivery Systems and Safety Perspectives
  AAPS PharmSciTech 2026 DOI: 10.1208/s12249-026-03400-y
  +Save
• pH-Sensitive Macromolecular Carriers: Targeted Therapeutics for Cancer and Inflammation
  Journal of Macromolecular Science, Part B 2026 DOI: 10.1080/00222348.2025.2466325
  +Save